Avalo Therapeutics, Inc. (AVTX) shares closed at $17.76, reflecting a 1% gain over the past four weeks. Wall Street analysts project a mean price target of $37.89, indicating a potential upside of 113.3%. The lowest estimate stands at $24.00—suggesting a 35.1% increase—while the most optimistic prediction sees the stock potentially reaching $50.00, an increase of 181.5%.
Over the last 30 days, the Zacks Consensus Estimate for AVTX’s current year earnings has risen by 22.3%, with four estimates moving higher and no negative revisions. The company holds a Zacks Rank of #2 (Buy), positioning it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors.
